RecruitingNot ApplicableNCT07511491

Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Cesarean Section

Effect of Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Cesarean Section: A Randomized Controlled Trial

Sponsor

Tanta University

Enrollment

90 participants

Start Date

Apr 11, 2026

Study Type

INTERVENTIONAL

Conditions

Prevention Shivering Cesarean Section Intravenous Ondansetron Lozenge

Summary

This study aims to compare the effect of ondansetron lozenge and intravenous for prevention of shivering in cesarean section (CS).

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 40 Years

Inclusion Criteria3

Age from 18 to 40 years.
American Society of Anesthesiology (ASA) physical status II.
Parturient women undergoing cesarean section under spinal anesthesia.

Exclusion Criteria9

Parturient women with any contraindication or hypersensitivity to the study drugs.
Any history of cardiovascular diseases, psychosis, hypertension, fetal distress, cord prolapse initial.
Preoperative shivering.
Preoperative fever (>38°C).
Body mass index > 40 kg/m2.
Medical history of alcohol or drug abuse.
Hypo- or hyperthyroidism.
Parkinson's disease or any extrapyramidal disease.
Intraoperative blood transfusion.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGOndansetron lozenge

Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.

DRUGOndansetron intravenous

Patients will receive 8 mg of ondansetron IV just before the surgery.

Locations(1)

Tanta University

Tanta, El-Gharbia, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07511491

Related Trials

Early General Anesthesia to Limit Experiences of Trauma During Cesarean Section-Pilot Study

NCT073344181 location

Determining the Optimal Dose of Intrathecal Morphine for Post-Cesarean Analgesia

NCT070234971 location